A drug with antiviral activity, with a strong effect on the virusHerpes simplex (HSV) types 1 and 2in vitro and herpes zoster virus. After entering the cells infected with the herpes virus, Acyclovir is phosphorylated to the active form - aciclovir triphosphate. The first stage of this process depends on the presence of HSV-sensitive thymidine kinase. Aciclovir triphosphate acts as an inhibitor and substrate for specific herpes viral DNA polymerase. In this way, it prevents the further synthesis of viral DNA without interfering with normal cellular processes. Aciclovir rapidly reaches the therapeutic concentration in the aqueous humor after penetration through the corneal epithelium.
Contraindications:
Hypersensitivity to Acyclovir, valaciclovir or excipients.
Precautions:
Immediately after applying the ointment a short, slight stinging sensation may occur.
Pregnancy and lactation:
The product should only be used during pregnancy if the expected benefit to the mother outweighs the risk of fetal exposure. There was no increase in the number of defects in children born to women who used aciclovir compared to the general population. There was also no cause and effect relationship between the occurrence of defects in children and the use by mothers of aciclovir during pregnancy. The product is excreted in human milk, breast-feeding is not recommended.
Side effects:
Very often: superficial, focal keratopathy (without visible consequences during healing, not requiring discontinuation of treatment). Common: transient, slight burning occurring immediately after application of the drug, conjunctivitis. Rarely: blepharitis. Very rare: hypersensitivity reactions including angioneurotic edema, urticaria.
Dosage:
The conjunctival sac is inserted about 1 cm ointment 5 times a day (every 4 h), with a night break. Treatment should be continued for at least 3 days after the symptoms disappear. Treatment should be started as soon as possible after the changes are observed.
(C)
